Status:
COMPLETED
Olopatadine 0.2% for the Treatment of Allergic Conjunctivitis
Lead Sponsor:
Alcon Research
Conditions:
Allergic Conjunctivitis
Eligibility:
All Genders
10+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to demonstrate that Olopatadine 0.2% is superior to vehicle in the treatment of the signs and symptoms associated with allergic conjunctivitis or rhinoconjunctivitis.
Eligibility Criteria
Inclusion
- History of seasonal allergic conjunctivitis or rhinoconjunctivitis, a positive grass antigen challenge reaction (skin test), and a positive response to grass in the Conjunctival Allergen Challenge (CAC) model
Exclusion
- Under 10 years of age
Key Trial Info
Start Date :
April 18 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 27 2006
Estimated Enrollment :
287 Patients enrolled
Trial Details
Trial ID
NCT00331500
Start Date
April 18 2006
End Date
July 27 2006
Last Update
August 14 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.